Display options
Cite
Kleinman NR, Lewandowska K, Culp LA. Tumour progression of human neuroblastoma cells tagged with a lacZ marker gene: earliest events at ectopic injection sites. Br J Cancer. 1994;69(4):670-9doi: 10.1038/bjc.1994.129.
Kleinman, N. R., Lewandowska, K., & Culp, L. A. (1994). Tumour progression of human neuroblastoma cells tagged with a lacZ marker gene: earliest events at ectopic injection sites. British journal of cancer, 69(4), 670-9. https://doi.org/10.1038/bjc.1994.129
Kleinman, N R, et al. "Tumour progression of human neuroblastoma cells tagged with a lacZ marker gene: earliest events at ectopic injection sites." British journal of cancer vol. 69,4 (1994): 670-9. doi: https://doi.org/10.1038/bjc.1994.129
Kleinman NR, Lewandowska K, Culp LA. Tumour progression of human neuroblastoma cells tagged with a lacZ marker gene: earliest events at ectopic injection sites. Br J Cancer. 1994 Apr;69(4):670-9. doi: 10.1038/bjc.1994.129. PMID: 7511405; PMCID: PMC1968801.
Copy Download .nbib Format: NLM
Share it on
Full text links
Nature Publishing Group Free PMC Article

Br J Cancer. 1994 Apr;69(4):670-9. doi: 10.1038/bjc.1994.129.

Tumour progression of human neuroblastoma cells tagged with a lacZ marker gene: earliest events at ectopic injection sites.

British journal of cancer

N R Kleinman, K Lewandowska, L A Culp

Affiliations

  1. Department of Molecular Biology and Microbiology, Case Western Reserve University, School of Medicine, Cleveland, Ohio 44106.

PMID: 7511405 PMCID: PMC1968801 DOI: 10.1038/bjc.1994.129
Free PMC Article

Abstract

Human Platt neuroblastoma cells were transfected with the marker gene, bacterial lacZ, to track cells at the earliest stages after ectopic injection at two different sites in athymic nude mice. Three clones (LZPt-1,-2 and -3) of differing morphologies were analysed. All clones yielded large primary tumours subcutaneously or intradermally with similar latency. While LZPt-2 and -3 clones generated well-staining primary tumours, LZPt-1 cells yielded many non-staining tumours, indicating greater instability of lacZ expression for this clone in situ (stability of lacZ expression in culture was similar for all three clones). After s.c. or intradermal injections, tumour cells were tracked for 1 h to > 3 weeks (palpable) to evaluate the topology and population expansion characteristics at the earliest times. From 1 h to 2 days, tumour cells were concentrated in central masses with 'crinkly hair' distributions emanating from the periphery. Between 3 and 7 days, these 'crinkly hair' patterns were cleared from the tissue, leaving dense ovoid patterns of tumour cells. These concentrations of cells expanded collectively, not by division of one or a few cells, but by division of many cells. For clone LZPt-1, cells stained well with X-gal for 2-3 days; by 7 days, most cells were non-staining. Evidence suggests that lacZ expression is turned off in these tumour cells, rather than a lacZ- cell type clonally dominating the population. For all three clones, tumour cells remained rounded and did not spread in any tissue environment at all time points, indicating very different matrix adhesion mechanisms operating in situ compared with their distinctive spreading patterns in culture. Angioneogenesis near primary tumours became evident by 2-3 days, leading to extensive vascularisation by 1-2 weeks. Overall, these studies indicate common tumour progression characteristics for three different clones of human neuroblastoma, insight into lacZ instability mechanisms operating in one of these clones and the earliest events in primary tumour formation for this tumour at two different ectopic sites.

Cited by

References

  1. Cancer Metastasis Rev. 1983;2(1):5-23 - PubMed
  2. Br J Cancer. 1993 May;67(5):910-21 - PubMed
  3. Cancer Res. 1987 Mar 1;47(5):1383-9 - PubMed
  4. J Cell Biol. 1988 Mar;106(3):931-43 - PubMed
  5. Cancer Res. 1988 May 1;48(9):2531-7 - PubMed
  6. Prog Clin Biol Res. 1988;271:17-29 - PubMed
  7. Prog Clin Biol Res. 1988;271:509-24 - PubMed
  8. Cancer Res. 1989 Jan 1;49(1):219-25 - PubMed
  9. J Lab Clin Med. 1989 May;113(5):561-8 - PubMed
  10. Cancer Res. 1990 May 1;50(9):2808-17 - PubMed
  11. J Cell Biol. 1990 Jun;110(6):2185-93 - PubMed
  12. Adv Cancer Res. 1990;55:87-132 - PubMed
  13. J Natl Cancer Inst. 1990 Sep 19;82(18):1497-503 - PubMed
  14. Cancer Res. 1990 Oct 15;50(20):6757-64 - PubMed
  15. Cancer Metastasis Rev. 1990 Jul;9(1):21-34 - PubMed
  16. N Engl J Med. 1991 Jan 24;324(4):219-26 - PubMed
  17. J Cell Biol. 1990 Dec;111(6 Pt 1):2733-45 - PubMed
  18. Int J Cancer. 1991 Apr 22;48(1):148-59 - PubMed
  19. J Natl Cancer Inst. 1991 Jul 17;83(14):1020-4 - PubMed
  20. Clin Exp Metastasis. 1991 Jul-Aug;9(4):363-75 - PubMed
  21. Int J Cancer. 1991 Sep 30;49(3):347-55 - PubMed
  22. Biotechniques. 1991 Sep;11(3):344-8, 350-1 - PubMed
  23. Cancer Metastasis Rev. 1991 Dec;10(4):311-9 - PubMed
  24. Cancer Metastasis Rev. 1991 Dec;10(4):321-33 - PubMed
  25. Cancer Res. 1992 Mar 15;52(6):1399-405 - PubMed
  26. Cancer Res. 1992 Apr 1;52(7):1737-43 - PubMed
  27. Cancer Res. 1992 Apr 15;52(8):2174-9 - PubMed
  28. Int J Cancer. 1992 Jun 19;51(4):620-6 - PubMed
  29. Lancet. 1992 Jun 13;339(8807):1453-7 - PubMed
  30. Clin Exp Metastasis. 1992 Jul;10(4):281-90 - PubMed
  31. Eur J Cancer. 1992;28A(12):1989-95 - PubMed
  32. Am J Pathol. 1992 Dec;141(6):1331-42 - PubMed
  33. Cancer Res. 1993 Jan 1;53(1):176-82 - PubMed
  34. Cancer Res. 1993 Jan 15;53(2):362-7 - PubMed
  35. Cancer Res. 1993 Feb 1;53(3):687-92 - PubMed
  36. Cancer Res. 1993 Mar 1;53(5):962-7 - PubMed
  37. Exp Cell Res. 1993 Feb;204(2):171-80 - PubMed
  38. Invasion Metastasis. 1992;12(3-4):197-209 - PubMed
  39. Lab Anim Sci. 1993 Feb;43(1):48-57 - PubMed
  40. Cancer Res. 1986 May;46(5):2203-7 - PubMed

Substances

MeSH terms

Publication Types

Grant support

LinkOut - more resources